By doing a lazy Friday arvo chatgdp search current SoC for GBM after surgery is Temozolomide which is worth around $200m in sales. Patent expiry was in 2013 before which annual sales were approx $920 million. So one could take a 3-5x sales figure from that and discount what you think is appropriate for the trial stage. My hope and guess would be well north of $15m.
CHM's Future, page-6
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.002(11.8%) |
Mkt cap ! $13.14M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.5¢ | $29.96K | 1.863M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 1574783 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 204621 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |